

# Datasheet: MCA1850FT

**BATCH NUMBER 180606**

<b>Description:</b>	MOUSE ANTI HUMAN CD99:FITC
<b>Specificity:</b>	CD99
<b>Other names:</b>	MIC2
<b>Format:</b>	FITC
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	DN16
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	25 µg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Product Form	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	FITC	490	525
Preparation	Purified IgG prepared by ion exchange chromatography		
Buffer Solution	Phosphate buffered saline		
Preservative	0.09% Sodium Azide		
Stabilisers	1% Bovine Serum Albumin		
Approx. Protein Concentrations	IgG concentration 0.1 mg/ml		

<b>External Database Links</b>	<b>UniProt:</b> <a href="#">P14209</a> <a href="#">Related reagents</a>
	<b>Entrez Gene:</b> <a href="#">4267</a> CD99 <a href="#">Related reagents</a>
<b>Synonyms</b>	MIC2, MIC2X, MIC2Y
<b>RRID</b>	AB_2076307
<b>Specificity</b>	<p><b>Mouse anti human CD99 antibody, clone DN16</b> recognizes human CD99, also known as E2 antigen, MIC2 or 12E7. CD99 is a 185 amino acid ~32 kDa single pass type I transmembrane O-glycosylated glycoprotein. Three isoforms can be produced by alternative splicing. Epitope analysis of the DN16 clone suggests the antibody recognizes a minimal peptide sequence "LPDNENKK" located between residues 32 and 39 towards the N-terminal region of the molecule. This sequence is present in both isoforms I and II but is largely absent from isoform 3 suggesting that the antibody will only recognize isoforms I and II (<a href="#">Gil et al. 2002</a>).</p> <p>CD99 expression is notable in the testis, pancreas, bone marrow, lymph nodes and spleen. CD99 is expressed on all classes of leukocytes and tends to be highest on immature cells.</p> <p>Functionally CD99 has been found to be involved in cellular adhesion/aggregation (<a href="#">Krisanaprakornkit et al. 2013</a>) and apoptosis (<a href="#">Sciandra et al. 2014</a>).</p>
<b>Flow Cytometry</b>	Use 10ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul.
<b>References</b>	<ol style="list-style-type: none"> <li>Choi, E.Y. <i>et al.</i> (1998) Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes. <a href="#">J Immunol. 161 (2): 749-54.</a></li> <li>Hahn, J.H. <i>et al.</i> (1997) CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. <a href="#">J Immunol. 159 (5): 2250-8.</a></li> <li>Kim, S.H. <i>et al.</i> (1998) Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). <a href="#">Blood. 92 (11): 4287-95.</a></li> <li>Kim, S.H. <i>et al.</i> (2008) Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. <a href="#">Blood. 95: 294-300.</a></li> <li>Husak, Z. <i>et al.</i> (2010) Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. <a href="#">J Leukoc Biol. 88: 405-12.</a></li> <li>Husak, Z. and Dworzak, M.N. (2012) CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity. <a href="#">Cell Death Dis. 3: e425.</a></li> <li>Hughes, S.F. <i>et al.</i> (2020) The role of phagocytic leukocytes following flexible ureteroscopy, for the treatment of kidney stones: an observational, clinical pilots-study. <a href="#">Eur J Med Res. 25 (1): 68.</a></li> </ol>

**Storage** Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10041 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA1850FT10041">https://www.bio-rad-antibodies.com/SDS/MCA1850FT10041</a>
<b>Regulatory</b>	For research purposes only

## Related Products

### Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA928F\)](#)

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)  
'M365805:200529'

Printed on 01 May 2024